Share on StockTwits

POZEN (NASDAQ:POZN) CEO John R. Plachetka 33,551 shares of the company’s stock in a transaction dated Tuesday, July 8th. Following the completion of the , the chief executive officer now directly owns 693,126 shares of the company’s stock, valued at approximately $6,148,028. The was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at TheStreet upgraded shares of POZEN from a “sell” rating to a “hold” rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.92.

POZEN (NASDAQ:POZN) traded up 1.14% during mid-day trading on Friday, hitting $8.85. 149,961 shares of the company’s stock traded hands. POZEN has a 1-year low of $4.92 and a 1-year high of $9.90. The stock’s 50-day moving average is $8.80 and its 200-day moving average is $8.46. The company’s market cap is $273.1 million.

POZEN (NASDAQ:POZN) last released its earnings data on Thursday, May 8th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.13. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $5.50 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. The company’s revenue for the quarter was up 433.5% on a year-over-year basis. Analysts expect that POZEN will post $0.58 EPS for the current fiscal year.

POZEN Inc (NASDAQ:POZN), is a pharmaceutical company focused on transforming medicine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.